Bank of America reissued their buy rating on shares of Becton Dickinson and (NYSE:BDX) in a research report sent to investors on Friday, Marketbeat reports. They currently have a $260.00 price target on the medical instruments supplier’s stock.

Several other research analysts have also recently weighed in on BDX. Zacks Investment Research cut Becton Dickinson and from a buy rating to a hold rating in a research report on Friday, January 5th. Evercore ISI initiated coverage on Becton Dickinson and in a research report on Wednesday, January 3rd. They issued an outperform rating and a $245.00 price objective on the stock. Citigroup raised Becton Dickinson and from a sell rating to a neutral rating in a research report on Friday, January 5th. Deutsche Bank set a $260.00 price objective on Becton Dickinson and and gave the stock a buy rating in a research report on Friday, December 29th. Finally, KeyCorp initiated coverage on Becton Dickinson and in a research report on Friday, January 5th. They issued an overweight rating and a $260.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $233.80.

Becton Dickinson and (NYSE:BDX) opened at $234.51 on Friday. The stock has a market capitalization of $53,800.00, a P/E ratio of 50.43, a P/E/G ratio of 1.79 and a beta of 1.07. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. Becton Dickinson and has a 1 year low of $169.19 and a 1 year high of $234.70.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. The company had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. Becton Dickinson and’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.12 earnings per share. research analysts forecast that Becton Dickinson and will post 10.66 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 8th were paid a $0.75 dividend. The ex-dividend date was Thursday, December 7th. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 annualized dividend and a dividend yield of 1.28%. Becton Dickinson and’s payout ratio is presently 64.52%.

Institutional investors and hedge funds have recently modified their holdings of the business. Westwood Holdings Group Inc. raised its stake in shares of Becton Dickinson and by 24.2% in the second quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock valued at $206,136,000 after buying an additional 205,721 shares during the period. Colony Group LLC raised its stake in shares of Becton Dickinson and by 2.1% during the 2nd quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock valued at $2,320,000 after purchasing an additional 239 shares during the period. State Street Corp raised its stake in shares of Becton Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after purchasing an additional 342,873 shares during the period. Peapack Gladstone Financial Corp raised its stake in shares of Becton Dickinson and by 1.3% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock valued at $7,116,000 after purchasing an additional 453 shares during the period. Finally, Zions Bancorporation raised its stake in shares of Becton Dickinson and by 23.7% during the 3rd quarter. Zions Bancorporation now owns 10,718 shares of the medical instruments supplier’s stock valued at $2,100,000 after purchasing an additional 2,050 shares during the period. Hedge funds and other institutional investors own 75.57% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Becton Dickinson and (BDX) Receives “Buy” Rating from Bank of America” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/01/22/becton-dickinson-and-bdx-receives-buy-rating-from-bank-of-america.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.